About Contact Us Careers

Antidepressants Market Size and Forecast, by Drug Class (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Tricyclic, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors); Indication (Major Depressive Disorder, Anxiety Disorder, Panic Disorder) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 4469
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT

Antidepressants Market Outlook:

Antidepressants Market size was over USD 16.92 billion in 2025 and is poised to exceed USD 23.18 billion by 2035, growing at over 3.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of antidepressants is estimated at USD 17.41 billion.

Antidepressants Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The growth of the market is primarily attributed to the worldwide increasing prevalence of depression coupled with growing public awareness concerning depression. According to the World Health Organization (WHO), an estimated 5% of adults worldwide suffer from depression. An individual's depression may be caused by a combination of emotional, behavioral, and genetic factors. Depression may be triggered by life events such as trauma, separation, or unemployed status. Depression can be treated effectively with antidepressants. Additionally, they prevent depression from returning and are effective in treating moderate, severe, and chronic depression.

Antidepressants are primarily intended to treat the symptoms of severe depression, such as feeling tired and down, as well as prevent them from recurring. Medications such as imipramine inhibit the process by which serotonin and norepinephrine are absorbed. Moreover, it inhibits the contraction of the detrusor and increases the resistance of the outlet through the contraction of the urethral sphincter. Additionally, the rising adoption of these drugs for the treatment of chronic pain coupled with rising instances of pain in chronic conditions are projected to drive market growth in coming years. For instance, worldwide nearly 772 million people are affected by chronic pain.

Key Antidepressants Market Insights Summary:

  • Regional Highlights:

    • North America antidepressants market will dominate over 46.5% share by 2035, driven by major depressive disorder, rising diagnoses, and healthcare spending.

  • Segment Insights:

    • The selective serotonin reuptake inhibitors segment in the antidepressants market is expected to achieve significant growth during 2026-2035, driven by the rising occurrence of major depressive and anxiety disorders.

  • Key Growth Trends:

    • Significant Rise in Stress Level
    • Increasing Approval for Novel Antidepressants

  • Major Challenges:

    • Side Effects Associated with Antidepressants
    • High Expenditure for Developing Antidepressants

  • Key Players: AbbVie Inc., Alkermes, Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline plc, Bristol-Myers Squibb Company.

Global Antidepressants Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 16.92 billion
    • 2026 Market Size: USD 17.41 billion
    • Projected Market Size: USD 23.18 billion by 2035
    • Growth Forecasts: 3.2% CAGR (2026-2035)

  • Key Regional Dynamics:

    • Largest Region: North America (46.5% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, China, Germany, United Kingdom, Japan
    • Emerging Countries: China, India, Japan, South Korea, Singapore

    • Last updated on : 10 September, 2025

Growth Drivers

  • Increasing Prevalence Of Mental Disorders Around The World - Mental disorders are aspects that affect a person's thinking, feelings, mood, and behavior. They are sometimes short-term or long-term (chronic). Such condition affects the ability of relating with other people and conditions on each day basis. Therefore, thorough and effective treatments are needed to combat these disorders. Therefore, the growing number of people suffering from mental illnesses and disorders is expected to drive the demand for antidepressants that are effective at treating such disorders. As per the World Health Organization statistics, 970 million individuals worldwide, or 1 in every 8 individuals, had a mental disorder in 2019.
  • Significant Rise in Stress Level – It has been observed that approximately 90% of Australians are stressed about one or more important aspects of their lives. An individual may suffer from depression if they are subjected to chronic, or long-term, stress. As a result, people are looking for safer and quicker medications to alleviate their stress level and treat depression.
  • Increasing Approval for Novel Antidepressants – For instance, in mid-2022, Axsome Therapeutics, Inc.’s Auvelity (dextromethorphan and bupropion) tablet received the approval from FDA to treat the major depressive disorder in adults.
  • Worldwide Increase in Geriatric Population - According to the World Health Organization data, the world's population of people aged 60 and up is expected to go up from 1 billion in 2020 to 1.4 billion by 2030. The global population of people aged 60 and up is expected to double to 2.1 billion by 2050. A significant burden of illness is associated with depression among the elderly. A number of antidepressants, such as SSRIs, have been shown to be effective in elderly patients suffering from major depression without psychosis.
  • Worldwide Rise in R&D Investment - The class of antidepressants has been tested in over a thousand randomized trials and research studies. Few drugs have achieved such success as antidepressants. The Unesco Institute for Statistics reports that, with an average annual growth rate of 4.7% over the past ten years, global R&D expenditure has expanded dramatically. (2010-2020). Globally, from 1.61% in 2010 to 1.93% in 2020, the percentage of global GDP invested on research and development has climbed significantly.

Challenges

  • Side Effects Associated with Antidepressants- There are many side effects associated with antidepressants, including drowsiness, blurred vision, headaches, sexual dysfunction, and a loss of emotional stability. Furthermore, SSRIs and SNRIs can cause nausea, anxiety, indigestion, as well as a rise in blood pressure. SNRI venlafaxine is not suitable for people who have serious heart conditions.
  • High Expenditure for Developing Antidepressants
  • Stringent Government Regulations On Drug Approval

Antidepressants Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Period

2026-2035

CAGR

3.2%

Base Year Market Size (2025)

USD 16.92 billion

Forecast Year Market Size (2035)

USD 23.18 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Antidepressants Market Segmentation:

Drug Class Segment Analysis

The global antidepressants market is segmented and analyzed for demand and supply by drug class into serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, serotonin antagonist & reuptake inhibitors, and others. Out of these, the selective serotonin reuptake inhibitors segment is projected to significantly grow over the forecast period on the back of growing occurrence of major depressive and anxiety disorders. For instance, anxiety disorders affected 301 million people in 2019, including 58 million children and adolescents. The most commonly prescribed antidepressants are selective serotonin reuptake inhibitors (SSRIs). It is most widely prescribed to treat depression, especially persistent or severe cases, in conjunction with talk therapy such as cognitive behavioral therapy (CBT). Additionally, these drugs have been demonstrated to treat other psychological conditions, which are expected to propel this segment's growth over the forecast period.

Our in-depth analysis of the global market includes the following segments:

      By Drug Class
  • Serotonin-Norepinephrine Reuptake Inhibitors
  • Selective Serotonin Reuptake Inhibitors
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Serotonin Antagonist & Reuptake Inhibitors

      By Indication
  • Major Depressive Disorders
  • Anxiety Disorder
  • Panic Disorder
  • Others
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Antidepressants Market Regional Analysis:

Regionally, the global antidepressants market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, North America region is expected to account for more than 46.5% market share by 2035, driven by major depressive disorder, rising diagnoses, and healthcare spending. For instance, in the United States, an estimated 20 million adults experienced at least one major depressive episode till 2020. This figure represented 8.6% of all adults in the region. As a result, such a burden of the disease will require the introduction of effective medications and antidepressant therapies. Moreover, increased awareness of treatment for resistant depression, fast approval of antidepressants in the region, and research and development initiatives are expected to drive the regional market growth over the forecast period.

Antidepressants Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Antidepressants Market Players:

    • AbbVie Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Alkermes
    • Sun Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Pfizer Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca PLC
    • GlaxoSmithKline plc
    • Bristol-Myers Squibb Company 

Recent Developments

  • AbbVie Inc., submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR) to the U.S. Food and Drug Administration (FDA) to treat major depressive disorder (MDD) in patients receiving existing antidepressants.

  • Alkermes, announced the receiving of Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD).

  • Report ID: 4469
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of antidepressants is estimated at USD 17.41 billion.

The global antidepressants market size was more than USD 16.92 billion in 2025 and is anticipated to grow at a CAGR of over 3.2%, reaching USD 23.18 billion revenue by 2035.

North America antidepressants market will dominate over 46.5% share by 2035, driven by major depressive disorder, rising diagnoses, and healthcare spending.

Key players in the market include AbbVie Inc., Alkermes, Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline plc, Bristol-Myers Squibb Company.

Antidepressants Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos